Dynacure SA Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Illkirch-Graffenstaden France

Primary Industry

Biotechnology

About

Based in Illkirch-Graffenstaden, France and founded in 2016, Dynacure SA operates as a biotechnology company that develops therapeutic drugs for the treatment of Myotubular and Centronuclear Myopathies (CNM). The company has 25 employees as of June 30, 2021 and was founded by its CEO, Stéphane van Rooijen, alongside Dr. Belinda Cowling. In April 2020, the company received its latest series C funding from a group of investors that included Andera Partners, Bpifrance, and Kurma Partners. The company's product is a therapeutic solution that provides treatment for neuromuscular diseases, including myotubular and centronuclear myopathies or CNM, and other rare diseases. It develops DYN101, an antisense oligonucleotide, or ASO, that serves as a modifying medicine for the treatment of the majority of CNM patients. It reduces the expression of dynamin 2 or DNM2, a protein in the body that an excessive amount might affect the muscle cells of the human system. The company also offers DYN201, a discovery stage program that develops a potential treatment for a group of rare inherited neurodegenerative disorders called hereditary spastic paraplegias or HSP. The company's revenue is generated by the sales of its therapeutic solutions DYN101 and DYN201 to patients suffering from Myotubular and Centronuclear Myopathies (CNM) and hereditary spastic paraplegias or HSP. Dynacure SA plans to conduct a Phase 1/2 trial in Europe of DYN101 and expand its trial to sites in the US in 2H21.

Current Investors

Idinvest Partners, Kurma Partners, Ionis Pharmaceuticals, Inc.

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Website

www.dynacure.com

Company Stage

Series C/Round 3

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.